MaaT Pharma is focused on developing microbiome-related therapies and its lead candidate is MaaT013, a treatment for acute ...

The UK biopharma company Alchemab Therapeutics announced today that it has joined forces with Eli Lilly to discover, develop, ...

Following a positive meeting with the FDA, BrainChild is getting ready to initiate a pivotal registration trial with its lead ...

The Phase 1a/b trial of ADRX-0405 is taking place at trial sites across the U.S., with first readouts expected in Q4 2025.

Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...